Skip to main content
All lobbying filings

ALSTON & BIRD LLP

Lobbying for TRAVERE THERAPEUTICS · Prescription pharmaceutical manufacturer of medications.

 Filing 2nd Quarter - Report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Income
$60,000.00
What the client paid this registrant for the period.
Client based in
California

Official filing document

 Lobbyists on this filing 1
  • ADAM NAVARA New on this filing
    Previously held: Legislative Fellow, Rep. Jan Schakowsky.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 4
  • HR 946
    ORPHAN Cures Act
  • HR 1518
    New Era of Preventing End-Stage Kidney Disease Act
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HR 1414
    Cameron’s Law
 Lobbying activity 5
Health Issues

Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients. Support of reauthorization of priority review voucher program. H.R.1, One Big Beautiful Bill Act, provisions regarding orphan drugs.

Medicare/Medicaid

Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation impacting products approved under the Accelerated Approval pathway. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients. H.R.1, One Big Beautiful Bill Act, provisions regarding orphan drugs.

Pharmacy

Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding orphan drug pricing, value, and reimbursement, relative to the Inflation Reduction Act of 2022 (Pub. L. No. 117-169, 136 Stat. 1818 (2022)). Policies regarding copay accumulators and impact on rare disease patients. Support of reauthorization of priority review voucher program. H.R.1, One Big Beautiful Bill Act, provisions regarding orphan drugs.

Medical/Disease Research/Clinical Labs

Legislation regarding clinical research for rare diseases and orphan drug development, and the Accelerated Approval pathway. Support of reauthorization of priority review voucher program.

Taxation/Internal Revenue Code

H.R.1414, Camerons Law, to restore the amount of the Orphan Drug Tax Credit. Legislation to improve education and care pathways for patients with rare kidney disease. H.R.1, One Big Beautiful Bill Act, provisions regarding orphan drugs.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem